Postavenie enzalutamidu v terapii metastatického hormonálne senzitívneho karcinómu prostaty // SOLEN

Onkológia S1/2026

The role of enzalutamide in the treatment of metastatic hormone-sensitive prostate cancer

Objective: The main objective of this case study is to highlight the opportunities of the treatment of metastatic hormone sensitive prostate cancer, including overall good tolerance of the therapy, maintenance of good quality of life and delaying the development of the castration resistant phase of the disease.

Case: We present a case of a patient initially diagnosed with metastatic hormone sensitive prostate cancer in whom the early intensification the therapy with ARPI (androgen receptor pathway inhibitors) along with androgen deprivation therapy (ADT) led to drop in the PSA < 0.2 ng/ml and this level is maintained 16 months after the treatment initiation.

Conclusion: Enzalutamide in addition to androgen deprivation therapy has got over all very good effect in the treatment of metastatic hormone sensitive prostate cancer.

Keywords: metastatic hormone sensitive prostate cancer, hormonal therapy, enzalutamide